1. Home
  2. PSNYW vs TENX Comparison

PSNYW vs TENX Comparison

Compare PSNYW & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

PSNYW

Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

HOLD

Current Price

$3.27

Market Cap

290.9M

ML Signal

HOLD

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$11.97

Market Cap

317.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSNYW
TENX
Founded
2017
1967
Country
Sweden
United States
Employees
1686
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
290.9M
317.8M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
PSNYW
TENX
Price
$3.27
$11.97
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$29.67
AVG Volume (30 Days)
4.7K
548.7K
Earning Date
03-06-2025
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,034,261,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$79.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$5.34
52 Week High
$7.50
$18.38

Technical Indicators

Market Signals
Indicator
PSNYW
TENX
Relative Strength Index (RSI) 46.42 44.13
Support Level $2.88 $10.87
Resistance Level $3.51 $12.75
Average True Range (ATR) 0.24 0.66
MACD 0.03 0.07
Stochastic Oscillator 40.58 55.56

Price Performance

Historical Comparison
PSNYW
TENX

About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

Polestar Automotive Holding UK PLC is a pure play, premium electric car brand, designing performance cars engineered to excite consumers and drive change. It believes that it defines market standards in design, innovation and sustainability. It is determined to improve society by accelerating the shift to sustainable mobility. The company conducts its business as one operating segment with primary commercial operations in Europe, North America, Asia Pacific and various importer markets. The company generates majority of revenue from United Kingdom.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: